AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Drdrew

Published November 9, 2026

Meth at 12, Heroin At 15: Bobby Lee on His Addiction, Relapse Battles, And 4 Years Of Sobriety

Read the full story at Drdrew

Americans for Ibogaine CEO Bryan Hubbard speaks on Texas's $50 million ibogaine trials, and what Stanford's research on veterans with traumatic.

Post on X

Share this story

Surfaced by this Google Alert

Ibogaine